CIK 0001582313
- Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- Operating
- EIN
- 980661854
- Phone
- +1 604-484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion | +6,172 | $3.56 | $22K | 18,277 |
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Shares withheld for taxes | −1,829 | $9.53 | $17K | 16,448 |
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion | +3,703 | $3.52 | $13K | 20,151 |
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Shares withheld for taxes | −1,098 | $9.53 | $10K | 19,053 |
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion | +3,115 | $3.73 | $12K | 22,168 |
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Shares withheld for taxes | −923 | $9.53 | $9K | 21,245 |
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion | +7,973 | $2.68 | $21K | 29,218 |
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Shares withheld for taxes | −1,687 | $9.53 | $16K | 27,531 |
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion | +785 | $2.68 | $2K | 28,316 |
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Shares withheld for taxes | −167 | $9.53 | $2K | 28,149 |
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Sale | −6,149 | $9.33 | $57K | 22,000 |
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion · Stock Option (Right to Buy) | −411 | 0 | ||
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion · Stock Option (Right to Buy) | −2,057 | 0 | ||
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion · Stock Option (Right to Buy) | −1,028 | 0 | ||
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion · Stock Option (Right to Buy) | −5,144 | 0 | ||
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion · Stock Option (Right to Buy) | −6,172 | 0 | ||
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion · Stock Option (Right to Buy) | −3,703 | 0 | ||
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion · Stock Option (Right to Buy) | −3,115 | 1,000 | ||
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion · Stock Option (Right to Buy) | −7,973 | 4,372 | ||
| 2015-09-22 | GOLDBERG Y. PAUL VP of Clinical Development | Exercise or conversion · Stock Option (Right to Buy) | −785 | 243 |
Page 37 of 42 · 836 trades